Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Income towards Parent Company: 2012-2025

Historic Income towards Parent Company for Agios Pharmaceuticals (AGIO) over the last 14 years, with Sep 2025 value amounting to -$103.4 million.

  • Agios Pharmaceuticals' Income towards Parent Company fell 110.91% to -$103.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$403.0 million, marking a year-over-year decrease of 160.06%. This contributed to the annual value of $673.7 million for FY2024, which is 291.35% up from last year.
  • Agios Pharmaceuticals' Income towards Parent Company amounted to -$103.4 million in Q3 2025, which was up 8.09% from -$112.5 million recorded in Q2 2025.
  • Agios Pharmaceuticals' Income towards Parent Company's 5-year high stood at $2.0 billion during Q1 2021, with a 5-year trough of -$112.5 million in Q2 2025.
  • Over the past 3 years, Agios Pharmaceuticals' median Income towards Parent Company value was -$91.3 million (recorded in 2023), while the average stood at $796,545.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first spiked by 4,382.87% in 2021, then slumped by 2,696.82% in 2022.
  • Quarterly analysis of 5 years shows Agios Pharmaceuticals' Income towards Parent Company stood at $4.0 million in 2021, then plummeted by 2,442.28% to -$92.7 million in 2022, then fell by 3.51% to -$95.9 million in 2023, then declined by 0.61% to -$96.5 million in 2024, then slumped by 110.91% to -$103.4 million in 2025.
  • Its Income towards Parent Company was -$103.4 million in Q3 2025, compared to -$112.5 million in Q2 2025 and -$90.5 million in Q1 2025.